login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock News
USA
- NASDAQ:EPRX -
CA29842P1053
-
Common Stock
5.48
USD
-0.01 (-0.18%)
Last: 10/23/2025, 1:16:22 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
EPRX Latest News, Press Relases and Analysis
All
Press Releases
23 days ago - By: Benzinga
Eupraxia Reports Encouraging Safety And Efficacy Data From Eosinophilic Esophagitis Study
24 days ago - By: Benzinga
- Mentions:
NBY
NEOG
PMI
APDN
...
12 Health Care Stocks Moving In Monday's After-Market Session
24 days ago - By: Eupraxia Pharmaceuticals Inc.
- Mentions:
EPRX.CA
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
a month ago - By: Eupraxia Pharmaceuticals Inc.
- Mentions:
EPRX.CA
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
6 months ago - By: Eupraxia Pharmaceuticals Inc.
- Mentions:
EPRX.CA
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May
a month ago - By: Eupraxia Pharmaceuticals Inc.
- Mentions:
EPRX.CA
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares
a month ago - By: Eupraxia Pharmaceuticals Inc.
- Mentions:
EPRX.CA
Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares
2 months ago - By: Eupraxia Pharmaceuticals Inc.
- Mentions:
EPRX.CA
First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI
2 months ago - By: Eupraxia Pharmaceuticals Inc.
- Mentions:
EPRX.CA
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
3 months ago - By: Eupraxia Pharmaceuticals Inc.
- Mentions:
EPRX.CA
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
4 months ago - By: Eupraxia Pharmaceuticals Inc.
- Mentions:
EPRX.CA
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
5 months ago - By: Eupraxia Pharmaceuticals Inc.
- Mentions:
EPRX.CA
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
6 months ago - By: Eupraxia Pharmaceuticals Inc.
- Mentions:
EPRX.CA
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025
6 months ago - By: Eupraxia Pharmaceuticals Inc.
- Mentions:
EPRX.CA
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
7 months ago - By: Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
8 months ago - By: Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Announces CFO Succession
a year ago - By: Eupraxia Pharmaceuticals Inc.
Eupraxia's DiffuSphereâ„¢ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
a year ago - By: Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
a year ago - By: Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
a year ago - By: Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
a year ago - By: Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
a year ago - By: Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
a year ago - By: Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
Please enable JavaScript to continue using this application.